Docoh
Loading...

GRFS Grifols SA - ADR - Level III

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

GRFS stock data

(
)

Calendar

9 Apr 21
18 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 0 NEW
Opened positions 1 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 1.32M 0 NEW
Total shares 75.1K 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Ovata Capital Management 75.1K $1.32M NEW
Largest transactions
Shares Bought/sold Change
Ovata Capital Management 75.1K +75.1K NEW

Financial report summary

?
Competition
OmnicellCerusProteoOrganovoQuotientArgen X SEMereo BiopharmaCabaletta Bio
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adjunct, adult, AEKSU, African, Aggrastat, Agrifood, aid, AkzoNobel, Ambassador, AmCham, Andorra, ANVISA, arisen, artificial, Atlantic, authorisation, BA, basket, Biden, bidirectional, big, bis, Boca, BPC, breadth, Britain, BSC, buildup, burdensome, buyback, capita, catering, CHF, CHIP, CHMP, Circular, clearer, CNY, coalition, Coated, coefficient, comment, concept, concurrent, consortium, Contigent, continent, contrast, covid, CPRA, Crohn, CT, DC, DCF, deferral, deployment, Dew, Dextrose, DHPR, digital, dihydropyridine, diplomat, discrepancy, DMF, DMS, downgraded, drew, EC, eCTD, Egypt, Egyptian, electricity, eleven, endpoint, England, entrusted, equiment, Eurocurrency, Europacific, expedient, fellow, fight, Film, Flebolex, Flexoblex, fora, fragmentation, FTT, gas, GBP, GC, GCAM, Glossary, Grifill, grounded, Guatemala, HBV, headcount, heard, HEV, hIVIG, HSA, Hygiene, ICE, IFX, IH, ILAP, infliximab, Inpatient, IRTA, ITAC, IVG, journal, JPY, JV, Kft, Korean, Lactate, lender, leukemia, lock, lymphocytic, lymphoma, MACRA, mar, membership, MHRA, Montreal, Museum, mutual, mutually, neuromuscular, NHP, NSPO, Oct, onset, ophthalmologic, Opulentia, ordinal, Padol, parameter, Parc, Parkinson, perimeter, PJT, Politecnica, pose, PQ, Prefilled, PrettyParty, programme, proteome, prudence, QSmart, quater, Quick, rapid, Raton, Reina, Rent, repurposed, resilience, revamped, RMS, Rodriguez, rolled, rolling, ROW, Sabadell, scenario, scholarship, SCIG, Scotland, Secuoya, slowdown, Sofia, South, Specimen, stabilisation, stalled, strictest, Supercomputing, suture, talent, Taskforce, Taul, Tavleese, Tavlesse, TDP, Tech, teleportation, template, Tennessee, tenure, TGA, therefrom, thrombocytopenia, tightly, turmoil, unaffected, unchanged, unclear, Unfettered, UNICEF, unprecedented, upsize, urban, voiding, wake, Week, wider, wording, worst
Removed: Abengoa, Abyntek, add, Agencia, Agriculture, al, Amerihealth, Anna, answered, antigen, apportioned, Arab, Arabian, Aradigm, Bayer, benchmarked, Boehringer, Boletin, Boston, budgeted, CAT, CCASG, Chiquito, chromatographic, Cologne, comfort, Commerce, complaint, contemplated, cooperation, corruption, Covidien, defrauded, demonstrated, detailing, disapprove, dosage, drag, embedded, enabled, enactment, engineer, Enzo, equip, ESCP, expandable, FCPA, federally, fell, funded, gained, Georgia, GSA, GTC, guarantor, Gulf, headquartered, Healthier, healthy, heart, hundred, Hypermune, Iberia, Iberica, implied, incidental, Ingelheim, initiate, Innovacion, intervene, invalidity, investigate, judgement, Jupiter, Kamada, Kuwait, Latina, lawsuit, leaseback, LinahiqTM, Lluch, Mallinckrodt, maturing, Medicamento, merged, milk, mixing, MoH, Mondragon, moved, Nomura, nonsteroidal, NSAID, Obra, Occupational, occupy, Oppenheimer, Opulenta, overlap, oversaw, Parvo, penetration, pipeline, pivotal, placebo, plasmacare, plasmin, Portland, prevail, Progensa, prohibiting, radiology, RC, recommend, reconsidered, refurbishment, registering, reimbursable, remunerate, renamed, repayable, revert, Rheinland, Robert, Schroeder, seal, sequential, SeraCare, Seville, slightly, smaller, standardize, Stanley, streamlined, streamlining, subpopulation, tag, Technetix, timeframe, toxicity, transgenic, transitioning, underwent, Unipersonal, unnecessary, unsealed, URC, Utillaje, Veiga, Vista, whistleblower, won, Wood, writing, wrongdoing, zone

Proxies

No filings

Patents

APP
Utility
Liposomal Ciprofloxacin Formulations with Activity Against Non-tuberculous Mycobacteria
14 Oct 20
Methods of treatment of NTM lung infections using formulations of liposoma ciprofloxacin.
APP
Utility
Method for Calibrating a Peristaltic Pump, Method for Dispensing a Quantity of Liquid by Means of a Peristaltic Pump and Device for Producing Sterile Preparations That Can Execute Said Methods
30 Sep 20
A method is for calibrating a peristaltic pump, and for dispensing a quantity of liquid by a peristaltic pump.
APP
Utility
pH-Modulated Formulations for Pulmonary Delivery
23 Sep 20
An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed.
APP
Utility
Container for a Solution of Human Plasma Proteins and Method for Obtaining Thereof
1 Jul 20
A container for a solution of human plasma proteins has a primary inner bag made up of a first multilayer polymer film with two outer layers of polyethylene (PE) and an intermediate layer of ethylene vinyl alcohol (EVOH) copolymer, and a secondary outer bag made up of a second multilayer film with layers of polyethylene terephthalate (PET)-silicon oxides (SiOx), oriented polyamide (OPA), polypropylene (PP)-silicon oxides (SiOx) and polypropylene (PP), referred to as multilayer PP-SiOx.
APP
Utility
Method for the Aseptic Filling of a Bag
24 Jun 20
Method for the aseptic filling of a bag with a pharmaceutical product or liquid which comprises the following steps: a) a first step in which the cap is inserted in the inlet of the bag; b) a second step in which said cap is raised and the pharmaceutical product or liquid concerned is introduced; c) a third step in which the cap is re-inserted in the inlet of the bag; and d) a fourth step in which the cap and the inlet of the bag are welded.